Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Sarepta Therapeutics Inc    SRPT

SAREPTA THERAPEUTICS INC

(SRPT)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Income Statement Evolution
Annual Income Statement Data
Actuals in M $ Estimates in M $
Fiscal Period December 2016 2017 2018 2019 (e) 2020 (e) 2021 (e)
Sales 5,42 155 301 390 610 1 125
EBITDA -261 -164 -331 -351 -312 586
Operating profit (EBIT) -267 -172 -344 -346 -227 193
Pre-Tax Profit (EBT) -267 -48,6 -363 -356 -262 173
Net income -267 -50,7 -362 -323 -234 151
P/E ratio -5,00x -64,7x -20,0x -33,1x -48,1x 72,3x
EPS ( $ ) -5,49 -0,86 -5,46 -4,63 -3,19 2,12
Dividend per Share ( $ ) - - - - - -
Yield - - - - - -
Reference price ( $ ) 27,430 55,640 109,130 153,250 153,250 153,250
Announcement Date 02/28/2017
09:03pm
03/01/2018
09:01pm
02/27/2019
09:05pm
- - -
Finances - Leverage
Actuals in M $ Estimates in M $
Fiscal Period December 2016 2017 2018 2019 (e) 2020 (e) 2021 (e)
Debt - - 49,7 - - -
Finance 302 648 - 686 589 583
Operating income (EBITDA) -261 -164 -331 -351 -312 586
Leverage
(Debt/EBITDA)
- - - - - -
Capital Expenditure 5,34 12,0 61,2 61,2 60,0 80,5
Book Value Per Share (BVPS) ( $ ) 6,15 13,4 15,6 18,5 16,5 23,3
Cash Flow per Share ( $ ) -5,05 -3,94 -5,87 -4,78 -2,54 1,30
Announcement Date 02/28/2017
09:03pm
03/01/2018
09:01pm
02/27/2019
09:05pm
- - -
Balance Sheet Analysis
Assessed data source
© 2019 S&P Global Market Intelligence
Financial Ratios

Size 2019e 2020e
Capitalization 11 364 M $ -
Entreprise Value (EV) 10 679 M $ 10 775 M $
Valuation 2019e 2020e
P/E ratio (Price / EPS) -33,1x -48,1x
Capitalization / Revenue 29,1x 18,6x
EV / Revenue 27,4x 17,5x
EV / EBITDA -30,4x -34,2x
Yield (DPS / Price) - -
Price to book (Price / BVPS) 8,28x 9,29x
Profitability 2019e 2020e
Operating Margin (EBIT / Sales) -88,7% -37,3%
operating Leverage (Delta EBIT / Delta Sales) - 0,61x
Net Margin (Net Profit / Revenue) -83,0% -38,3%
ROA (Net Profit / Asset) -16,1% -19,5%
ROE (Net Profit / Equities) -28,5% -37,9%
Rate of Dividend - -
Balance Sheet Analysis 2019e 2020e
CAPEX / Sales   15,7% 9,85%
Cash Flow / Sales -90,9% -30,9%
Capital Intensity (Assets / Sales) 5,14x 1,96x
Financial Leverage (Net Debt / EBITDA) - -
EPS & Dividend